Navigation Links
Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:5/17/2011

WAYNE, N.J., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago, IL.  

"Bayer has built a pipeline of oncology compounds, including several in late-stage development, and our researchers are working tirelessly to advance their development," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee.  "At ASCO, we are presenting data from studies evaluating these compounds."  

Bayer-sponsored Phase II and III studies evaluating the investigational compounds in Bayer's pipeline being presented at ASCO include:

Radium-223 Chloride

  • Alkaline Phosphatase (ALP) Normalization and Overall Survival in Patients With Bone Metastases From Castration-Resistant Prostate Cancer (CRPC) Treated with Radium-223
    • Abstract #4620, Genitourinary Cancer Poster Session
    • Sunday, June 5, 8:00 am - 12:00 pm, Hall A, Poster Board 7D

Radium-223 chloride is an investigational agent and is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other Health Authorities.

About Oncology at Bayer

Bayer is committed to advancing the science of cancer, and translating this science into therapies that can help people with cancer live longer.  With several compounds in clinical development, Bayer's oncology portfolio demonstrates the Company's commitment to developing innovative cancer therapies.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidi
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)... 2014   BioNano Genomics , the genome ... centers to purchase an Irys™ System . Among ... Institute (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope ... a comprehensive view of a genome was a ... not deliver the scalability or reliability to detect ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... 2012 Omnicell, Inc. (NASDAQ: OMCL ), a leading ... for its fourth quarter and year ended December 31, 2011. ... of 2011 was $62.9 million, up $5.7 million or 9.9% ... or 2.3% from the third quarter of 2011. Revenue for ...
... 26, 2012 ResMed Inc. (NYSE: RMD ) today ... 31, 2011.  Revenue for the quarter ended December 31, 2011 ... on a constant currency basis) over the quarter ended December ... income was $62.9 million, an increase of 8%, compared to ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full Year 2011 Results 2Omnicell Announces Fourth Quarter and Full Year 2011 Results 3Omnicell Announces Fourth Quarter and Full Year 2011 Results 4Omnicell Announces Fourth Quarter and Full Year 2011 Results 5Omnicell Announces Fourth Quarter and Full Year 2011 Results 6Omnicell Announces Fourth Quarter and Full Year 2011 Results 7Omnicell Announces Fourth Quarter and Full Year 2011 Results 8Omnicell Announces Fourth Quarter and Full Year 2011 Results 9Omnicell Announces Fourth Quarter and Full Year 2011 Results 10Omnicell Announces Fourth Quarter and Full Year 2011 Results 11ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011 2ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011 3ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011 4ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011 5ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011 6
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... Ebola while working for NBC News in Liberia has ... isolation unit at Nebraska Medical Center in Omaha, where he had ... A blood test confirmed by the U.S. Centers for Disease ... to Providence, R.I., NBC News reported Tuesday night. ...
(Date:10/20/2014)... Wakefield, MA (PRWEB) October 20, 2014 ... be sponsoring a booth at the American Foundation for ... October 25th. The AFSP is a not-for-profit organization that ... year. Net proceeds from these events are used to ... research, but education and personal relationships as well. ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... artemisinin-based combination therapies to prevent malaria //parasites from developing ... the National Agency for Food and Drug Administration and ... the parasite already has grown resistant to chloroquine and ... be difficult to find another malaria treatment. ...
... Court has issued notices to the state government and Delhi ... teacher at its Doha branch claiming Rs 1.5 million for ... after preliminary arguments on former teacher Vibha Kapur's plea, Justice ... chairman to file their replies by April 3. ...
... Hopkins Scleroderma Center together with engineers from the university's ... monitor that// checks a patient's finger for symptoms of ... device seem to be promising: ,The Ambulatory ... secured with a bandage or medical tape. It contains ...
... The U.S. Food and Drug Administration (FDA) today ... Complex (Human), Alphanate. //The product is approved for ... Willebrand disease (vWD) in whom the hormone desmopressin ... approved for patients with severe vWD (Type 3) ...
... All India Institute of Medical Sciences (AIIMS) director P. ... public relation officer filed a police complaint against him. ... relation officer of AIIMS, has filed a police complaint ... accusing Venugopal of harassment, wrongful restraint from entering office, ...
... British scientists have developed a house to help people with ... a warning when it thinks there may be a problem. ... Institute of Medical Engineering could mean elderly people with fading ... rather than being forced to go into care homes, reported ...
Cached Medicine News:Health News:Ex-teacher Sues Delhi Public School 2Health News:Space-Age Bandage Monitors Patients With Raynaud's Disease 2Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:‘Smart House’ Developed to Monitor People With Dement 2
Ergotec Vetriretinal Instrument System. Ultra-fine 2.8 mm jaws. Angled 55 degrees. 20 gauge shaft. 25 mm in length with black tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. Ultra-fine angled tips (4 mm) with 20 gauge shaft. 25 mm in length. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. 2 mm pointed tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left. Most popular size or model....
Medicine Products: